NorthWest Biotherapeutics Inc (NWBO)

[Gus1212]

Are we falling behind? Maybe a little

(Reuters) - The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, which targets tumors with specific genetic mutations, irrespective of where in the body the disease started, the agency said on Thursday.

The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling. It is approved to treat certain types of solid tumors, which show rare genetic anomalies called NTRK fusions.

Individually, the mutations are rare and it is difficult to run dedicated tests for each. They have been identified in a broad range of solid tumor types, including breast, colorectal, pancreatic and non-small cell lung cancers, the company said.